PD-L1 is commonly upregulated on many different tumor types, where it inhibits anti-tumor T cell responses, and that PD-1 is expressed on the majority of tumor-infiltrating lymphocytes That is an important rationale to block this pathway as novel cancer immunotherapies. The gene discussed is PDCD1; the disease is neoplasm.